PTO/SB/08 (2/92) Sheet 1 of 1

1/2	TATRAD	9//						eetiori	
Form PTO-1449				Attorney's Docket No. 39750-0065DV1		plication S 621,855	erial No.		
INFORMATION DISCLOSURE STATEMENT				Applicant(s) Frederic J. de SAUVAGE, et al.					
(use several sheets if necessary)				Filing Date: July 16, 2003		Group Art Unit: 1653 /649			
2.0			<u>U.S.</u>	PATENT DOCUMENTS				Parties.	
Examiner Ref. Date Initials No.		Date	Document No.	Name	Clas	Subcla ss	Filing Date (if appropriate)		
16.			 	 N.PATENT:DOCUMENTS					
Examiner Initials	Ref.	Date	Document No.	Name	Clas	Subcla ss	Translation YES NO		
IIIIII ais .	140.	<del> </del>	<del> </del>	<del></del>	<del>                                     </del>				
		Pack	and the second of the second o	THER DOCUMENTS hor, title, date, pertinent pages, e	tc.)				
Examiner Initials ,	Ref. No.	Title	· .	·					
Andres et al., Development 128(10):3685-3695 (2001)  Multiple effects of artemin on sympathetic neurone generation, survival and grov							d growth	•	
	2	Baloh et al., Neuron 21: 1291-1302 (1998)							
	ł	Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex.							
	3	Esteva, "Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast							
		Cancer," The Oncologist 9(Suppl 3):4-9 (2004), page 6, column 1, lines 8-16).							
	4	Negro et al., Recent Prog Horm Res. 59:1-12 (2004) Essential roles of Her2/erbB2 in cardiac development and function.							
	5			al Research 51:435-441 (2002)					
	· .			us Growth Hormone Secretog					
	6	Smith et	al., Best Pract Re	s Clin endocrinol Metab. 18(3)	:333-347				
				ogues: prospects and potenti	al pitfalls	•	,		
	7	Thilenius	s et al., <i>Eur. J. Imn</i>	nunol. 27(5):1108-1114 (1997)					
1/				ligand mediate different sensi	tivity to d	leath in th	e signalin	g	
		pathway	s of Fas and cytop	lasmic mutants.					
		L)	· · · · · · · · · · · · · · · · · · ·	DATE CONSIDERE	· · · · · · · · · · · · · · · · · · ·	<del></del>			
EXAMINER:	11	rayer	·		31	21/06		·	
EXAMINER:	Initial if	citation con	sidered, whether or	not the citation conforms with Minclude a copy of this form with ne	PEP 609. I	Draw a line	through th	е	
*If an asteris	is place	ed beside th	ne reference number	a copy is not provided because	the refere	nce was pre	eviously cli	ed by or	
submitted to U.S.C. §120.	the PTO	in a prior a	pplication that is ide	ntical in the statement and relied	upon for	an earlier fi	ling date u	nder 35	

**FORM PTO-1449** 

Ref

No.

Examiner

Initials

,U.S. Dept. of Commerce

Atty Docket No. 39766-0065 DV1 Serial No. 10/62/ To be Assigned

Patent and Trademark Office

Applicant

Frederic J. de SAUVAGE, et al.

Subclass

Filing Date 7/16/0 Herewith

Class

To be Assigned-

Filing Date

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

**Document Number** 

Date

## U.S. PATENT DOCUMENTS

Name

(3.	*1	5,709,858	20.01.98	Godowski et al.	14 54	143.	<b>.</b>				
.,	FOREIGN PATENT DOCUMENTS										
xaminer nitials		Document Number	Date	Country	Class	Subclass	Translation Yes No				
707	<b>*</b> 2	307,247	15.03.89	EPO			1				
	• 3	846,764	10.06.98	EPO		l	1				
1 1	+4	WO 93/06116	01.04.93	per WIPO		1	<b>†</b> 1				
1	*5	WO 97/33912	18.09.97	PET WIPO	· .		1 1				
1 1	• 6	WO 97/44356	27.11.97	per wipo		}	1				
	• 7	wo 98/53069	26.11.98	Det WIPO			l				
	• B	WO 98/54213	03.12.98	POT WIPO			<u> </u>				
$\mathbf{V}$			1	} <sup></sup>	ì	1 .					

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

		Official processing finding Admini Tages and
RY	• 9	Arenas et al., "GDNF Prevents Degeneration and Promotes the Phenotype of Brain Noradrenergic Neurons in Vivo" Neuron 15:1465-1473 (1995).
7	*10	Baloh et al., "Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRα3-RET receptor complex" Neuron 21(6):1291-1302 (Dec 1998)
	*11	Beck et al., "Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain" Nature 373:339-341 (1995)
	•12	Berkemeier et al., 'Neurotrophin-5: A Novel Neurotrophic Factor That Activates trk and trkB' Neuron 7:857-866 (November 1991).
T	-13	Bolivar et al., "Construction and Characterization of New Cloning Vehicles. II. A Multipurpose Cloning System" Gene 2:95-113 (1977)
	-14	Buj-Bello et al., "GDNF Is an Age-Specific Survival Factor for Sensory and Autonomic Neuron 15:821-828 (1995).
	•15	Cash et al., 'Parkinson's disease and dementia: Norepinephrine and dopamine in locus ceruleus' <u>Neurolog</u> 37:42-46 (1987).
	•16	Chan-Palay et al., "Alterations in Catecholamine Neurons of the Locus Coeruleus in Senile Dementia of the Alzheimer Type and in Parkinson's Disease With and Without Dementia and Depression' The Journal of Comparative Neurology 287:373-392 (1989).
	*17	Durbec et al., *GDNF signalling through the Ret receptor tyrosine kinase* Nature 381:789-793 (1996)
	*18	Hefti, F., "Nerve Growth Factor Promotes Survival of Septal Cholinergic Neurons After Fimbrial Transections" J. of Neuroscience 6(8):2155-2162 (August 1986).
	19	Henderson et al., 'GDNF: A Potent Survival Factor for Motoneurons Present in Peripheral Nerve and Muscle' Science 266:1062-1064 (1994).
1	*20	Heumann, R., "Regulation of the Synthesis of Nerve Growth Factor" J. Exp. Biol. 132:133-150 (1987)
$\bigvee$	*21	Hirano, A., "Cytopathology of Amyotrophic Lateral Sclerosis" Advances in Neurology: Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases, Lewis P. Rowland, Raven Press, Ltd., Chapter B, Vol. 56:91-101 (1991)

**EXAMINER:** 

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation c in rms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication tapplicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing dat under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

and the second of the second s

4 PTO-1449

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

11 S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No. 39766-0065 DV1

Serial No. 10/62185

Applicant

Frederic J. de SAUVAGE. et al.

Filing Date . 7/16/03

Group' 1649
To be Assigned

xaminer Ref. OTHER DISCLOSURES (Including Author, Title, Date; Pertinent Pages, etc.) litials No. Hirsch et al., "Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease Nature 334:345-348 (1988), \*22 Holmes et al., "Structure and Functional Expression of a Human Interleukin-8 Receptor" Science 253(5025):1278-1280 (Sep 13, 1991). \*23 Hornykiewicz, O., "Neurochemical Pathology and the Etiology of Parkinson's Disease: Basic Facts and Hypothetical Possibilities Mt. Sinai J. Med. 55:11-20 (1988) \*24 Jing et al., "GDNF-Induced Activation of the Ret Protein Tyrosine Kinase Is Mediated by GDNFR-lpha, a Novel Receptor for GDNF\* Cell 85:1113-1124 (1996) Jing et al., "GFRu-2 and GFRu-3 Are Two New Receptors for Ligands of the GDNF Family" Journal of Biological Chemistry 272(52):33111-33117 (Dec 26, 1997), •26 Kaisho et al., "Cloning and expression of a cDNA encoding a novel human neurotrophic factor" FERS Letters 266(1,2):187-191 (June 1990) \*77 Kearns et al., "GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo" Brain Research 672:104-111 (1995) •28 Kotzbauer et al., "Neurturin, a relative of glial-cell-line-derived neurotrophic factor" Nature 384:467-470 (1996) Leibrock et al., "Molecular Cloning and Expression of Brain-derived Neurotrophic Factor" Nature \*30 341:149-152 (September 14, 1989) Lin et al., "GDNF: A Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons" Science 260:1130-1132 (1993), •31 Maisonpierre et al., "Neurotrophin-3: A Neurotrophic Factor Related to NGF and BDNF" Science 247:1446-1451 (March 23, 1990) \*32 Marcyniuk et al., "The Topography of Cell Loss from Locus Caeruleus in Alzheimer's Disease" J. Neurol. Sci. 76:335-345 (1986). •33 Melton et al., 'Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter Nucleic Acids Research 12(18):7035-7056 (Sep 25, Moore et al., "Renal and neuronal abnormalities in mice lacking GDNF" Nature 382:76-79 (1996). • 35 Oppenheim et al., 'Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF' Nature 373:344-346 (1995) 36 Phillips et al., "Widespread expression of BDNF but not NT3 by target areas of basal forebrain •37 cholinergic neurons\* Science 250(4978):290-294 (Oct. 12, 1990) Pichel et al., "Defects in enteric innervation and kidney development in mice lacking GDNF' Nature +3B 382:73-76 (1996) Rosenthal et al., 'Primary Structure and Biological Activity of a Novel Human Neurotrophic Factor" •39 Neuron 4:767-773 (May 1990). Ruppert et al., "Cloning and Expression of Human TAF11250: a TBP-associated Factor Implicated in 40 Cell-cycle Regulation Nature 362:175-179 (1993), Sanchez et.al., 'Renal agenesis and the absence of enteric neurons in mice lacking GDNF' Nature •41 382:70-73 (1996).

EXAMINER:

DATE CONSIDERED:

3/27/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was pr viously cited by or submitted t the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

	7.			<u> </u>		
1	1 PTO-1	· .	Atty Docket No. 39766-0065 DV1	Serial No. 10/62/853		
7		Patent and Trademark Office	Applicant			
LIST	OF DIS	CLOSURES CITED BY APPLICANT	Frederic J. de SAUVAGE, et al.			
. (L	Jse sev	eral sheets if necessary)	Filing Date 7/16/03	Group 1649  To be Assigned		
iner Is	NI.	OTHER DISCLOSURES (Including Author, Title, Date,	Pertinent Pages, etc.)			
<b>E</b> H		Sompayrac et al., Efficient infection of monkey cells with DNA Sci. USA 78(12):7575-7578 (Dec 1981)				
	-43	Stromberg et al., 'Glial Cell Line-Derived Neurotrophic Factor Adult Striatum and Stimulates Developing Dopamine Neurons in Vi	is Expressed in the vo* Exp. Neurol, 124	Developing but Not :401-412 (1993).		
1	+44	Thimmappaya et al., "Adenovirus VAI RNA is required for efficie times after infection" Cell 31(3 Pt 2):543-551 (Dec 1982)	nt translation of vi	ral mRNAs at late		
T	*45	Thoenen et al., "Physiology of Nerve Growth Factor" Physiologic	al Reviews 60(4):128	4-1335 (October 1980)		
	*46	Tomac et al., Protection and repair of the nigrostriatal dopam 373:335-339 (1995)				
	-47	Treanor et al., "Characterization of a multicomponent receptor	•			
	748	Trupp et al. "Functional receptor for GDNF encoded by the c-re (1996),				
	*49	Yan et al., 'In vivo neurotrophic effects of GDNF on neonatal a 373:341-344 (1995)	ind adult facial moto	r neurons" <u>Nature</u>		
<b>T</b>						
			· · · · · · · · · · · · · · · · · · ·			
				•		
	-			<del></del>		
	<u> </u>		· · · · · · · · · · · · · · · · · · ·			
		·		· · · · · · · · · · · · · · · · · · ·		
				<u> </u>		
	1-			·		

3/27/06 EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

**EXAMINER:** 

\*If an asterisk is placed beside the reference number, a copy is n t provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

**DATE CONSIDERED:** 

Form PTO-1449					Attorney's Docket No.	cket No. 39766-0065 DV1 Application Serial No. 10/62/835 T <del>o be Assigned</del>					
IN	IFOR	MATIC	N DISCLO	SURE STATEMENT	Applicant(s)  Frederic J. de SAUVAGE, et al.						
(use several sheets if necessary)					Filing Date: Herewith	7/16/03	Grou	ip Art Unit:	To be Assigned		
		36 36	iciai silect	3 11 11 00 00 00 11 77	U.S. PATENT DOCUMENT	S**	\$ #E		學的學樣	7 1 <b>40</b> 7 (	
Examin	er	Ref.	Date	Document No.	Name		lass	Subclass	Filing Date (if appropr		
Initials		No.									
33 XX		e de la companya de l	- 104 374 (**)	FC	REIGN PATENT DOCUME					73.55.32.22.2	
Examin Initials	er	Ref. No.	Date	Document No.	Country	C	lass	Subclass	Transla YES	NO	
	1				GB				<del> </del>		
			<u> </u>			eastable 1700 高速中央 2014年1796		A11 A21 FU 5 69		4913	
				(including	OTHER DOCUMENTS	pages, etc.)		7			
Examin Initials	,	Ref. No.	Title					- 4		(4004)	
(1C)-		50.*	Classen-Welsh, L., "Signal Transducton by the PDGF Receptors", <i>Progress in Growth Factor Research</i> – 5:37-54 (1994)  Kammer, W., et al., "Homodimerization of Interleukin-4 Receptor & Chain Can Induce Intracellular Signaling", <i>The</i>								
	į	51.*	I Journal d	of Riclanical Chemistry -	. 271(39): 23634-23637 (1996)						
		52.	Phospho Chemisti	orylation of Stat5 and Tra	nal Growth Factor Receptor/J Insduces a Growth Signal in (1996)	Hematopoietic Cells	s", The	Journal of	Biological	osine	
	,	53.*	Nishino,	J., et al., "GFRα3, a Con	nponent of the Artemin Rece eron – 23:725-736 (1999)						
	$\dashv$	54.*	Rudinge	r, J., "Peptide Hormones	", (ed. J.A. Parsons) Univers	ity Park Press, Balti	imore,	рр. 1-7 (197	6)		
									<u> </u>		
	$\dashv$										
	$\dashv$										
			<u> </u>								
			<del>                                     </del>								
<del></del>	_		<del> </del>	·							
I	- 1								<del>.</del>		

	$\frown$	/		<del>,,,</del>
EXAMINER:	, //\v	eyer	DATE CONSIDERED: 3	127/06
EXAMINER: Initial if	itation	considered, whether or not the citation con	forms with MPEP 609. Draw a li	ne through the citation if not in

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the ref\_rence number, a copy is not provided because the reference was previ\_usly\_cited by or submitted t\_the PTO in a prior application that is identical in the statement and reli\_d up\_n f\_r an\_arlier filing dat\_under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

(use several examiner   Finitials   Finitials   Finitials   Finitials   Finitial examiner   Finitial exami	ST.  veral  Ref. No.	ATEME	if necessary) U.S. Document No.	Applicant(s) Frederic J Filing Date: July 16, 2003 PATENT DOCUMENTS Name	Gro	VAGE, e	ti	1987		
Examiner F Initials N	Ref. No.	Date	Document No.	July 16, 2003 PATENT DOCUMENTS	16 Clas	<del>53-</del> 16°	19	<u> इंग्रेस्टर</u>		
Initials N	No.	4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Document No.			Subcla				
Examiner F	Ref.		FOREIG			SS	Filing Da	te		
Examiner F	Ref.		, rukeiu	N PATENT DOCUMENTS						
Initials   N		Pale	Document No.	Name	Clas s	Subcla ss	Transl YES	• • • • • • • • • • • • • • • • • • • •		
Examiner F	Ref.	Title	 	THER DOCUMENTS hor, title, date, pertinent pages,	elc)					
	No.	Andres et al., Development 128(10):3685-3695 (2001)  Multiple effects of artemin on sympathetic neurone generation, survival and growth								
2	2	Balan et al., Neuron 21: 1291-1302 (1998)  Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex								
3	3 /	Esteva, "Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer," The Oncologist 9(Suppl 3):4-9 (2004), page 6, column 1, lines 8-16).								
LEATONS 5	4	Essentia	al roles of Her2/erl	Horm Res. 59:1-12 (2004) bB2 in cardiac development a	and function	on				
		Rosická et al., Physiological Research \$1:435-441 (2002) Ghrelin - a New Endogenous Growth Hormone Secretogoguel								
6		Smith et al., Best Pract Res Clin endocrinol Metab. 18(3):333-347 (2004) Growth hormone secretogogues: prospects and potential pitfalls								
7	7	Agonist	s et al., <i>Eur. J. Imi</i> antibody and Fas s of Fas and cyto	munol./27(5):1108-1114 (1997 ligand mediate different sen plasmic mutants	) sitivity to c	death in th	e signalin	9		
5×4440/50		/		DATE CONSIDER	ED:					
EXAMINER:		· · · - · · · · · · · · · · · · · · · ·								
citation if not in	s place e PTO	rmance a d beside t in a prior	nd not considered. In the reference number application that is identified.	r not the citation conforms with I include a copy of this form with r ir, a copy is not provided becaus entical in the statement and relie	ext commu	nication to	applicant. eviously cit	ed by or		

Juplied